TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19563186
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with oral administration of Flunarizine Hydrochloride vacuity capsules, thrice each week for 4 weeks.
Study: 19563186
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Flunarizine Hydrochloride capsules combined with acupuncture at placebo-points, thrice each week for 4 weeks.
Study: 16889569
Drug: TCC locked
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCC locked with cefotaxime (10 mg/mL) and heparin (5000 U/mL)
Study: 16889569
Drug: TCC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCC with heparin (5000 U/mL) alone
Study: 9425400
Drug: GHRH infusion
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH infusion
Study: 9425400
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + GHRP-2 infusion
Study: 8505663
Drug: Albendazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (600 mg single dose)
Study: 18462303
Drug: Compeed cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compeed cold sore patch (CSP)
Study: 18462303
Drug: Acyclovir cream
Normalized name: Acyclovir Cream
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir cream 5%
Study: 9252517
Drug: loxiglumide (CCK-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: loxiglumide (CCK-A antagonist)
Study: 1492262
Drug: Ampicillin/sulbactam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (1.0 g/0.5 g) with probenecid (1 g)
Study: 1492262
Drug: Ceftriaxone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (0.25 g)
Study: 29380728
Drug: Everolimus (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (1.5 mg twice daily)
Study: 20953593
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg (4.86 μmol)
Study: 17114888
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) in patients with active acromegaly (AA)
Study: 17114888
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) in group A controls
Study: 17114888
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test (ITT) in patients with growth hormone deficiency (GHD)
Study: 17114888
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test (ITT) in group B controls
Study: 12412171
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen (Arm Y: every 4 weeks; Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Study: 12412171
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen (Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Study: 10807190
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet regimen (lamivudine 150 mg/zidovudine 300 mg twice daily plus a protease inhibitor)
Study: 10807190
Drug: Conventional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen (150 mg lamivudine twice daily, 600 mg zidovudine daily, and a protease inhibitor)
Study: 10807190
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet regimen
Study: 8794812
Drug: Estrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen supplementation (estradiol valerate, 2 mg daily, n = 6)
Study: 6465489
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release morphine 20 mg
Study: 24559810
Drug: Ginger powder
Normalized name: Emergen-C Turmeric & Ginger Powder for Solution (Citrus-Ginger)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger powder supplementation (3 one-gram capsules daily for 8 weeks)
Study: 24559810
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 one-gram microcrystalline-containing capsules daily for 8 weeks)
Study: 17921390
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg Zn/d as a supplement
Study: 16173138
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (12.5 mmol daily for 6 weeks)
Study: 12549635
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (without Tamsulosin)
Study: 10553163
Drug: IL‐3 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐3 (10 microg/kg/day, s.c., day 1‐5) followed by G‐CSF (5 microg/kg/day, day 6‐8)
Study: 10553163
Drug: IL‐3+G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐3+G‐CSF
Study: 26474174
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus icotinib (125 mg thrice daily for 4-8 months)
Study: 21263367
Drug: Intermittent propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent propofol sedation (bolus of 2-4 mg/kg, followed by repeat boluses of 0.5-2 mg/kg/dose as needed)
Study: 21263367
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol sedation (bolus of 2-4 mg/kg, followed by continuous infusion of 100 μg/kg/min with 1-mg/kg/dose boluses)
Study: 19100061
Drug: Coxsackievirus binding
Normalized name: coxsackievirus A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in DCM patients
Study: 19100061
Drug: Coxsackievirus binding
Normalized name: coxsackievirus A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in healthy adults
Study: 12883406
Drug: Sufentanil effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil effect site concentration of 0.5 ng/ml (group 1)
Study: 12883406
Drug: Sufentanil effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil effect site concentration of 1.25 ng/ml (group 4)
Study: 12883406
Drug: Mean arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure, heart rate, time to tracheal extubation, awareness, satisfaction scores, morphine requirements
Study: 2054278
Drug: Chlorpheniramine 4
Normalized name: chlorpheniramine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 4 mg with paracetamol 650 mg
Study: 29384326
Drug: 75‐g 2‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75‐g 2‐h oral glucose tolerance test (OGTT)
Study: 25197908
Drug: Real ear
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real ear acupressure (EAP) treatment
Study: 25197908
Drug: Sham ear
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ear acupressure (EAP) treatment
Study: 21187618
Drug: 5.25% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% sodium hypochlorite solution
Study: 12208796
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Study: 12208796
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Study: 12208796
Drug: Antibiotics (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (both regimens)
Study: 1823064
Drug: Ranitidine injection
Normalized name: ranitidine Injection
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine injection (5 minutes before pentagastrin)
Study: 1823064
Drug: Ranitidine injection
Normalized name: ranitidine Injection
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine injection (1 hour before pentagastrin)
Study: 1823064
Drug: Short-term oral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oral intake of ranitidine
Study: 30118784
Drug: Nutrition and
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition and Culinary in the Kitchen (NCK) Program, 6-week duration, 3 hours weekly, including hands-on cooking classes and a food market visit
Study: 26952222
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine infusion at a rate of 1.5mg/kg/min
Study: 26952222
Drug: IV esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV esmolol infusion at a rate of 1mg/kg/min
Study: 20388562
Drug: Partial rectal
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial rectal wall advancement flap (Group I)
Study: 18821872
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for alcohol dependence (details on specific medications or behavioral interventions not provided)
Study: 18821872
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for alcohol dependence
Study: 12795130
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of bupivacaine
Study: 12795130
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of morphine
Study: 6349743
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of emepronium bromide and flavoxate hydrochloride
Study: 30419226
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg, 3 times daily, started 4 hours before the ascent)
Study: 30419226
Drug: Acetazolamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (125 mg, twice daily, started the night before the ascent)
Study: 28462933
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behaviour therapy (group‐CBT) added to standard spinal cord injury inpatient rehabilitation (SR)
Study: 25613747
Drug: Intravenous GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GIP (4 pmol/kg/min)
Study: 22447467
Drug: Candesartan, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan, 12 mg monotherapy (group A)
Study: 22447467
Drug: Hydrochlorothiazide (HCTZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ), 6.25 mg in combination with candesartan, 8 mg (group B)
Study: 16998171
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patches (6-week reducing dose regimen)
Study: 8466240
Drug: Protein restricted
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein restricted diet (0.8‐1.1 g/kg/day)
Study: 30824408
Drug: Oxaliplatin-based chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-based chemotherapy (Ox)
Study: 25667123
Drug: Achillea millefolium
Normalized name: ACHILLEA MILLEFOLIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea millefolium distillate solution (15 mL gargled 4 times a day for 14 days)
Study: 25667123
Drug: Routine solution
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine solution (15 mL gargled 4 times a day for 14 days)
Study: 16873950
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg coenzyme Q(10) soft oil capsules
Study: 16873950
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg coenzyme Q(10) soft oil capsules
Study: 16873950
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg crystalline Q(10) powder capsules
Study: 23803687
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment (TBI SOLO)
Study: 9354315
Drug: Frusemide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide + Meloxicam (15 mg)
Study: 3006414
Drug: Naloxone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (8 mg bolus in 20 ml normal saline)
Study: 24946562
Drug: Compound Wuzhigan
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Wuzhigan capsules (2 capsules one time, three times a day for 3 days)
Study: 24946562
Drug: Compound Wuzhigan
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Wuzhigan tablets (4 tablets one time, three times a day for 3 days)
Study: 29943163
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg for 8 weeks
Study: 22001942
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg for 4 weeks
Study: 9814473
Drug: Human CG
Normalized name: CG-200745
DrugBank: CG-200745 (DB12259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human CG (10 U/mL)
Study: 9814473
Drug: Interleukin (IL)-1
Normalized name: M-1095 (anti-interleukin (il)-17a/f single-domain antibody)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin (IL)-1 (10 ng/mL)
Study: 9814473
Drug: Interleukin (IL)-4
Normalized name: interleukin-4
DrugBank: Binetrakin (DB12182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin (IL)-4 (10 ng/mL)
Study: 9814473
Drug: Interleukin (IL)-10
Normalized name: interleukin-10
DrugBank: Interleukin-10 (DB12880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin (IL)-10 (10 ng/mL)
Study: 2468927
Drug: Cicloprolol (0.025,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloprolol (0.025, 0.025, 0.05, and 0.1 mg/kg)
Study: 7095
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg) + Flunitrazepam (2 mg)
Study: 7095
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg)
Study: 31456003
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (RT) with single doses of 0.5Gy (total dose 3.0-5.0Gy)
Study: 31456003
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (RT)
Study: 25868059
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg zinc sulfate containing 50 mg zinc)
Study: 22509642
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (5 doses of 2.5 ml each, one dose per week)
Study: 22509642
Drug: Methylprednisolone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (single 2 ml dose)
Study: 19874153
Drug: High-dose naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naltrexone (100 mg/d)
Study: 19874153
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) without Contingency Management (CM)
Study: 15365066
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) every 3 weeks for four cycles
Study: 9423999
Drug: 22.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 Gy in five daily fractions
Study: 2958947
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (4.8 X 10(6) units im plus 1.0 g of oral probenicid)
Study: 2958947
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin (3.5 g plus 1.0 g of oral probenicid)
Study: 6240786
Drug: Spectinomycin (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin (2.0 g im)
Study: 2958947
Drug: Oral rosoxacin
Normalized name: rosoxacin
DrugBank: Rosoxacin (DB00817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rosoxacin (300 mg)
Study: 27260149
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 μg/kg (Group I)
Study: 27260149
Drug: Intranasal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal clonidine 3 μg/kg (Group II)
Study: 27260149
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline 0.5 ml (Group III)
Study: 19912160
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Infusion
Study: 16409700
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment, no counselling)
Study: 11151875
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral erythromycin
Study: 1334539
Drug: cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2, days 1, 3, 5) (PE)
Study: 1334539
Drug: cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2, days 1, 3, 5)/ifosfamide (2 g/m2, days 1, 2, 3) (PEI)
Study: 6466532
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lower dose range of glycopyrrolate and atropine)
Study: 21696081
Drug: 0.5% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isobaric racemic bupivacaine 3 mL
Study: 21696081
Drug: 0.5% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isobaric levobupivacaine 3 mL
Study: 18713312
Drug: Acid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid infusion (HCl 0.15 mol L(‐1))
Study: 18713312
Drug: Acid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid infusion aspirated 3 cm distally
Study: 16710092
Drug: Remifentanil (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.25 microg.kg(‐1) continuous infusion)
Study: 12456442
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.6 mg) combined with epidural neostigmine (60 micro g)
Study: 12456442
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine (60 micro g)
Study: 12456442
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.6 mg)
Study: 2024911
Drug: Enalapril/Hydrochlorothiazide (E/HCTZ:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/Hydrochlorothiazide (E/HCTZ: 20/12.5-40/25 mg)
Study: 2024911
Drug: Enalapril (E:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (E: 20-40 mg)
Study: 2024911
Drug: Hydrochlorothiazide (HCTZ:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ: 12.5-25 mg)
Study: 7282909
Drug: Preventive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive antibiotic treatment with clindamycin and gentamycin
Study: 6356004
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic therapy
Study: 6421007
Drug: ISDN (Isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (Isosorbide dinitrate) - mean dose 15.5 micrograms kg‐1 min‐1
Study: 6421007
Drug: NTG (Nitroglycerin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG (Nitroglycerin) - mean dose 5.5 micrograms kg‐1 min‐1
Study: 29924642
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg every 8 hours
Study: 26414108
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAPT) - aspirin plus clopidogrel plus cilostazol (100 mg loading, followed with 50 mg twice per day) for 3-6 months
Study: 6806218
Drug: 200 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 rad daily to total tumor doses of 6000-7000 rad in 6-7 weeks
Study: 6806218
Drug: 400 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 rad daily to a total of approximately 4400 rad in 2-3 weeks
Study: 30563042
Drug: GOX treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOX treatments (low and high H2 O2 production rates)
Study: 22460367
Drug: Group vocal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group vocal improvement program (7 weekly lectures on anatomy, vocal hygiene, and vocal exercises)
Study: 18338474
Drug: Methylergometrine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylergometrine (0.2 mg) after delivery of placenta
Study: 10193676
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times a day)
Study: 10193676
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg once a day)
Study: 2305995
Drug: TTFCA 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 60 mg tid (Group A)
Study: 2305995
Drug: TTFCA 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 30 mg tid (Group B)